// App-Quantinova.ai

: MNGI-12. EXPRESSION OF PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) IN MENINGIOMA: CLINICAL UTILITY FOR PREDICTION OF TUMOR RECURRENCE AND ASSOCIATION WITH HYPOXIC RESPONSE AND NFKB2 ACTIVATION

Researchers

Presenter

  • Shirin Karimi

Principal Investigators

  • Suganth Suppiah

  • Sheila Mansouri

  • Farshad Nassiri

  • Yasin Mamatjan

  • Jeff Liu

  • Kenneth Aldape

  • Gelareh Zadeh

Medical Centers

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

  • Division of Neurosurgery & MacFeeters-Hamilton Center for Neuro-Oncology, University Health Network, Princess Margaret Cancer Center, Toronto, ON, Canada

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved